返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Attends 14th Cardiac Imaging & Cardiac Interventional Summit

[2017-08-11] 

Beijing, China – From July 21 to July 23, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the 14th Cardiac Imaging & Cardiac Interventional Summit held in Beijing and hosted a case competition. Themed on "Collaboration, Innovation, Concentration, Intelligence," the congress focused on the latest advancement of cardiovascular imaging, precise treatment under the guidance of multimodal imaging, new technologies of coronary interventional treatment, as well as case studies and operation demonstrations.
 
The opening ceremony was chaired by Professor Yundai Chen of Chinese PLA General Hospital and "Princess CICI," a robot of Chinese PLA General Hospital which can work as a guiding-nurse to assist the physicians and help patients. Princess CICI had good interaction with Professor Chen and introduced the experts in attendance one by one. The appearance of Princess CICI demonstrated the main theme of the congress "Collaboration, Innovation, Concentration, Intelligence." The future development of cardiac imaging will leverage new technologies of cardiovascular imaging and intervention as well as artificial intelligence to expand the application of imaging technology in the treatment of cardiovascular diseases and fundamental researches, and promote precise medicine.
 
On July 22, MicroPort® hosted a case competition and invited cardiologists from all over China to share and discuss the treatment of complex cases. The first half was co-chaired by Professor Qin Qin of Tianjin Chest Hospital, Professor Jincheng Guo of Beijing Luhe Hospital of Capital Medical University, Professor Yu Wang of Chinese PLA General Hospital, and Professor Jiancheng Xiu of Nanfang Hospital of Southern Medical University. After fierce competition, the case "Accidental Stent Deformation in the Treatment of RCA Bifurcation Lesion" by Professor Guowei Zhou of Shanghai General Hospital won the first place. The second part was co-chaired by Professor Jinghua Liu of Beijing Anzhen Hospital of Capital Medical University, Professor Zhexun Lian of the Affiliated Hospital of Qingdao University, Professor Dongxing Ma of Wujing Hospital, Professor Jiancheng Xiu of Nanfang Hospital of Southern Medical University, and Professor Zhijun Sun of Chinese PLA General Hospital. In the end, the case "Treatment of Left Main Bifurcation Lesions under the Guidance of IVUS" by Professor Tao Tian of Fuwai Hospital of Chinese Academy of Medical Sciences took the crown.
 
Since 2016, MicroPort® hosted the case competition in various national-level congresses such as South China International Congress of Cardiology and Oriental Congress of Cardiology, and has received positive feedback. Such activity builds an academic platform for experts to learn from each other and achieve progress by discussing and sharing the treatment of complex cases. In the future, MicroPort® will continue to organize similar academic activities to promote the diagnosis and treatment technology of interventional cardiology and benefit more domestic patients.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® Orthopedics Holds the Second TKA Training Course in Hong Kong
[Next]:Reewarm™ Gains CFDA Approval